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Summary 
One approach towards the development of a vaccine against malaria is to immunize against the 
parasite sexual stages that mediate transmission  of the parasite from man to mosquito.  Anti- 
bodies against these stages, ingested with the blood meal, inhibit the parasite development in 
the mosquito vector, constituting "transmission  blocking immunity." Most epitopes involved 
in transmission-blocking  immunity depend on the tertiary conformational structure of surface 
antigens. However, one of the transmission-blocking monodonal antibodies we have raised against 
Plasmodium vivax reacts with a linear epitope on both asexual stages and gametes. This mono- 
clonal antibody (A12) is capable of totally blocking development of the parasite in the mosquito 
host when tested in membrane feeding assays with gametocytes from P. vivax-infected patients. 
Immune screening of a P. vivax Xgtll genomic expression library with A12 led to the isolation 
of a clone to which was mapped the six-amino acid epitope recognized by A12. Antisera raised 
in mice against a 12-mer synthetic peptide containing this epitope coupled to bovine serum al- 
bumin not only had high titers of antipeptide  antibodies  as measured by enzyme-linked im- 
munosorbent assay, but in addition recognized the same 24- and 57-kD parasite components 
as A12 on Western blots and reacted with the parasite by immunofluorescence.  When tested 
in membrane feeding assays, these antibodies have significant suppressive effects on parasite devel- 
opment in the mosquito. 
T 
ransmission-blocking  vaccines against malaria are based 
on immunity mediated by antibodies  against  parasite 
sexual stages. These antibodies block the development of the 
malaria parasite in the mosquito host (reviewed in reference 
1).  Such vaccines, while not protecting the vaccinated in- 
dividual, would prevent subsequent transmission of the para- 
site. They would thus be effective at a community level, both 
by reducing transmission  and also by preventing the spread 
of parasites rendered resistant through drug or immune pres- 
sure exerted on asexual blood stages. It has been demonstrated 
that Plasraodium vivax patients can readily develop antibodies 
against  parasite  sexual stages  (2).  This  leads  to  natural 
transmission-blocking immunity that significantly lowers the 
incidence of infection (3). The ability of antibodies to block 
parasite transmission or suppress infectivity is tested by mere- 
brane feeding,  a biological  assay that  directly  reflects the 
phenomenon arising in naturally infected patients (described 
in reference 4). 
mAbs with transmission-blocking  activity have allowed 
the definition of specific targets of transmission-blocking im- 
munity on the surface of P. falciparura sexual stages (5, 6). 
Several genes coding for these target antigens have now been 
cloned (Pfs25, [7] Pfs48/45 [8], and Pfs230 [9]). Such cloning 
was achieved through screening libraries with oligonudeo- 
tide probes, the sequence of which was derived from micro- 
sequencing of purified parasite antigens, not through immune 
screening  of  expression  DNA  libraries.  This  is  because 
transmission-blocking  antibodies  predominantly recognize 
conformationally dependent epitopes  that  are not usually 
suitably reproduced in Escherichia coli (1). 
357  J.  Exp.  Med.  ￿9  The Rockefeller  University Press ￿9 0022-1007/95/01/0357/06 $2.00 
Volume 181  January 1995  357-362 Because of the lack of significant cross-reactive immunity 
and of DNA cross-hybridization between R falciparum  and 
P. viva.x, the characterization of species-specific  molecules which 
are targets of transmission-blocking immunity, is required 
for the development of  an effective  vivax transmission-blocking 
vaccine. We have characterized such molecules through iso- 
lation of several transmission-blocking mAbs (described  in 
reference 10). All but one of these antibodies recognize epi- 
topes that depend on tertiary structures of the parasite  sur- 
face antigens and are thus not good candidates for screening 
expression libraries constructed in E. cog However, the difficul- 
ties inherent in obtaining large quantities ofP. vivax parasites 
(this parasite  cannot be maintained in long-term cultures), 
limit the use of protein purification and micro-sequencing 
as the basis  for cloning relevant  genes. 
Here we describe the use of a R vivax transmission-blocking 
mAb (A12),  which recognizes a linear epitope, to identify 
a clone upon immune-screening of a kgtll R  vivax expres- 
sion library. The six amino acids which encompass the linear 
epitope recognized by this mAb have been mapped within 
the translated amino acid sequence of this done and the ability 
of a corresponding peptide assessed for its ability to elicit 
transmission-blocking or infectivity-suppressing antibodies. 
Antibodies raised in mice against a synthetic peptide com- 
prising this epitope have the capacity to significantly sup- 
press infectivity of the parasite in the mosquito, as measured 
by membrane feeding assays. Both the monoclonal and mono- 
specific polyclonal antibodies recognize the same parasite com- 
ponents on Western blots and react  with sexual as well as 
asexual stage parasites by immunoftuorescence. 
Materials and Methods 
Parasite Material.  P, vivax gametocytes for membrane feeding 
experiments and Western blots were obtained, under informed con- 
sent, from patients admitted to the Colombo General Hospital in 
Sri Lanka.  Female  gametes were prepared as described  in Munesinghe 
et al. (4). Parasites used for all nucleic acid studies were obtained 
from Saimiri sciureus monkeys (Guyana phenotype) infected with 
the P. vivax Belem isolate. Purified parasites were prepared and ex- 
tracted for DNA as detailed in (11), for RNA by the method of 
Chomczynski and Sacchi (12) or were resuspended  in nonreducing 
SDS-PAGE sample buffer for Western blots (13). Immunofluores- 
cence slides were prepared from infected human or monkey blood. 
Immunofluorescence  on air-dried slides was performed as described 
(13) with the modification  of  5% FCS added  to incubation  solutions. 
mA&  The mAb A12 was raised against the surface ofP. vivax 
asexual stage parasites. It has previously been described (13). 
Library Production and Screening.  The R  vivax genomic DNA 
library, has been incviously  described (11). Both the Xgtll and pGex 
libraries were constructed through DNasel digestion of DNA in 
the presence of manganese, based on the method of Mattei et al. 
(14). Antibody screening was carried out on 10  s phage from the 
unamplifled kgt11 library or 5,000 pGex colonies, on appropriate 
filters containing 10 mM IPTG (isopropyl-/3-n-thiogalactoside), 
using the A12 mAb ascitic fluid and iodinated protein A (Amer- 
sham France SA, Les Ulis, France). Sequencing was carried out 
according to dideoxy technology using the Sequenase kit (United 
States Biochemical  Corp., Cleveland,  OH) as recommended  by the 
manufacturers. Other DNA techniques were carried out based on 
standard protocols of (15). 
SDS-PAGE and Western Blot Analysis.  Approximately 2 x  107 
parasites were loaded  onto 10% mini SDS-PAGE gels and migrated 
under  reduced conditions,  using  prestained molecular weight 
markers (Bio-Rad  Laboratories,  Hercules, CA). Western blots were 
carried out in a Bio-Rad Mini Trans-Blot Cell. Antibodies were 
diluted appropriately and reacted with alkaline phosphatase-con- 
jugated anti-mouse second antibody (diluted 1:7,500) and appro- 
priate substrates (Promega, Madison, WI). 
Peptide Synthesis.  A set of  46 peptides was purchased from Cam- 
bridge Research Biochemicals  Ltd. (Northwich, Cheshire, UK). 
Each peptide consisted of 12 residues overlapping by one amino 
acid, bound to a solid polyethylene  pin support in the same layout 
as a standard  ELISA  plate. The mAb culture supematant was reacted 
against these pins and revealed  using an antimouse (Promega) con- 
jugate  diluted  1:2,000. This was carried out according to  the 
manufacturer's  recommendations,  except that the antibody and con- 
jugate were diluted in 1% vol/vol FCS, 0.1% vol/vol Twcen-20, 
0.1% wt/vol BSA in 0.01 M PBS, pH 7.2, instead of the solution 
given in the protocol.  Free synthetic peptides (>95%  pure by 
HPLC) were produced at the Pasteur Institute Organic Chemistry 
Unit, using solid-phase technology containing a cysteine residue 
for conjugation to activated  BSA using the Imject activated  Super- 
Carrier system (Pierce, Rockford, IL). 
Immunization Protocols.  6-8-wk-old female  BALB/c  mice (Iffa- 
Credo, L'Arhresle,  France)  were used throughout. Peptide  constructs 
were used to immunize 10 mice per group, with 25/zg i.p. of con- 
jugated peptide-BSA in a total volume of 100/~1 per mouse using 
aluminium hydroxide (Pierce) as adjuvant (final concentration 2 
rag/100/zl). Fusion proteins were used to immunize five mice per 
group, with 50 #g i.m. per mouse using Freund's complete and 
incomplete adjuvant. After initial immunization, mice  were boosted 
every 3 wk and bled 7 d after boosting. 
ELISA.  Antibody titers were tested for individual mice after 
every  immunization with the peptide conjugates, by ELISA  either 
employing free peptide as antigen or appropriate peptide coupled 
to KLH as carrier. 96-well  plates (Nunc, Roskilde, Denmark) were 
routinely coated at 0.5/~g/ml quenched in PBS-Tween-gelatin  and 
revealed using horseradish peroxidase anti-mouse conjugate (Pro- 
mega) diluted 1:2,000. Plates were read at 405 nm (490 value sub- 
tracted automatically) via a plate reader (Molecular Devices; Palo 
Alto, CA) and corresponding software. 
Membrane Feeding Assays.  Each assay was carried out using 
gametocyte-infected  blood from a P. vivax patient. For each assay, 
150/zl of infected erythrocytes was resuspended in 75/zl of mouse 
antipeptide sera and 75/~1 of normal AB human sera. This was 
fed to 50 female Anopheles tessellatus mosquitoes in a membrane- 
feeding apparatus prewarmed to 37~  Nonfed mosquitoes were 
subsequently  removed  and the fed mosquitoes maintained at 26~ 
•  2~  The number of oocysts developing in the mid gut was 
examined microscopically  after 7 d (4). 
Results and Discussion 
Upon the immune-screening of a Agtll P. vivax genomic 
expression library with the A12 mAb, a clone was identified 
which contained a 1.5-kb insert. Upon induction, a recom- 
binant fusion protein was produced in E. coli corresponding 
to 132 kD on reduced SDS-PAGE gels, indicating a parasite 
component of "~16 kD. The translated amino acid sequence 
bore no significant homology to sequences in the GenBank 
358  Vivax  Malaria Transmission  Blocking Abs against A Peptide database (release 82), using a BLAST search (16) (data not 
shown). 
To identify the linear epitope of this P. vivax transmission- 
blocking mAb, a sublibrary corresponding to the kgt11 clone 
was constructed in a bacterial expression system. DNasel- 
generated fragments were prepared according to previous pro- 
tocols (14), EcoRI linkered and ligated into the pGex expres- 
sion vector (17). These clones were then screened with the 
A12 mAb. Out of 25 putative clones, 23 constructs expressing 
the A12 epitope were confirmed by Western blot analysis. 
Corresponding DNA sequences  were obtained using plasmid- 
specific oligonudeotide primers, and ranged between 96 and 
402 bp, all clones overlapping with 100 bp at the 3' end of 
the coding sequence. 
One of these constructs (done 21, Fig. 1) was used to im- 
munize BALB/c mice and the sera obtained reacted on Western 
blots of either P. vivax asexual stages or gametocytes extracted 
under reducing conditions.  The antibodies produced upon 
immunization with the fusion protein identified the same 
pattern of bands as the original  mAb A12, corresponding 
to a more intense 24-kD band plus an additional band of 57 
kD, as estimated from reduced SDS-PAGE gels, (Fig. 2 A, 
panels I  and 2). 
From an analysis of the DNA sequence encoding the open 
reading frame in phase with the Glutathione S-Transferase 
(GST) fusion protein of the smallest of the pGex clones, (done 
21, Fig. 1 B), the A12 epitope was mapped to a 32-amino 
acid region, corresponding to the COOH-terminal region 
of the predicted protein. To further delimit the A12 epitope 
sequence, synthetic peptide pin technology was employed. 
46 overlapping peptides corresponding to this region were 
constructed and incubated with the A12 mAb. This map- 
ping revealed the epitope of the monoclonal to consist of the 
six amino acids: TWEVLH (Fig. 1 A). A 12-mer peptide 
(Ep: CPLPTWEVLHDGS), corresponding to the predicted 
amino acid sequence containing this epitope was synthesized. 
As a control, a peptide  representing  the "Universal  T  cell 
epitope" from the P. fakiparum  CS protein,  (Tu: EKKIAK- 
MEKASSVFNWCG) (18) was employed. Peptides were cou- 
pled to a BSA carrier before immunization of BALB/c mice 
using aluminium hydroxide (Alum) as adjuvant, the only ad- 
juvant currently accepted for human use. 
Upon two immunizations with the Ep peptide, antibodies 
were produced which reacted with the same pattern on para- 
site Western blots as the A12 mAb (Fig. 2 A, lanes I  and 
3). The presence of a higher molecular weight band (~65 
kD) on Western blots when both the epitope peptide and 
control sera are reacted with the gamete antigen is probably 
due to the presence of human serum albumin contaminating 
this antigen preparation. The fact that the profiles on Western 
blotting are otherwise identical indicates that the target mol- 
ecule recognized by these antibodies may indeed be present 
in both asexual as well as sexual blood stage parasites, unlike 
other targets of transmission-blocking  immunity described 
to date (1). A12 and antipeptide sera demonstrated reactivity 
with the parasite, both with asexual parasites and with fe- 
male gametes on immunofluorescence.  There was no reac- 
tivity with the control peptide  sera at the dilutions  tested 
(1120-11500). 
Each mouse serum sample was tested for reactivity indi- 
vidually  by ELISA  then pooled for use in transmission-blocking 
assays. Individual mice ELISA titers are not shown but were 
highly uniform throughout each group of mice. The antiepi- 
tope titers for the pooled sera used in membrane-feeding anal- 
ysis are shown in Fig. 3. Antibody titers specific  to both pep- 
tides reached high levels even  after the second immunization 
A  2.0 
B 
1.5 
1.0 
￿9 
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[GSSPGQPLPTWEVLHDGSSFTIAVGGRRPNRQ 
Figure  1.  (A) Mapping  of the 
transmission-blocking  mAb  A12 
epitope using overlapping peptides 
derived from the pGex expression 
clone 21. The 46 peptides, each over- 
lapping by one residue, are shown 
on the x  abscissa plotted  against 
the absorption  value  on  reaction 
with the mAb.  The deduced epi- 
tope (TWEVLH) is highlighted in 
the black box.  (B) The translated 
amino acid sequence  of clone 21, the 
smallest DNA fragment  obtained 
able to encode a fusion protein rec- 
ognized by the A12 mAb, the epi- 
tope shown in boldface. The com- 
plete sequence  data are available  from 
EMBL/GenBank/DDBJ under ac- 
cession number X82416. 
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Figure  3.  ELISA  titers of  pooled sera used in membrane-feeding  assays 
from the third and fifth immunizations. The uncoupled  peptide  at 3/~g/ml 
was used as antigen. Plates were coated and serum incubated overnight 
at 4~  before second antibody incubation at 37~  for 3 h. Ep indicates 
the A12 epitope sera and Tu, the control sera. (I-7) Ep third immuniza- 
tion; (A) Ep fifth immunization bled after 7 d; (us) Ep fifth immuniza- 
tion bled after 22 d; and (A) Ep fifth immunization bled 44 d after immu- 
nization. All the Tu sera give very low absorption (<0.20D40s-490 U) 
when tested against the Ep peptide. The reciprocal  of the dilution is shown 
on the x abscissa (Dilution). 
Figure 2.  (A) Western  blots of  reduced R vivax antigen  from either asexual 
(a) or gamete (c) preparations, reacted with the A12 mAb in lane I, the 
pGex clone 21 recombinant sera (third immunization) in lane 2, and the 
epitope peptide antibodies in lane 3, consisting of the antibody pool em- 
ployed in membrane feeding, fifth immunization. Control antisera raised 
against the control peptide and pGex GST fusion protein alone are illus- 
trated in lanes 4 and 5, respectively.  All sera  were employed  diluted 1/400. 
(B) Immunofluorescence  of air-dried parasite antigen from asexual stages 
and gamete preparation reacted with the epitope peptide antibodies. Sera 
was diluted 1/250; the control peptide antisera gave no fluorescence  at 
this dilution and is not shown. 
(data not shown) and subsequent boosts did not significantly 
increase these titers. 
The antipeptide sera were tested in 10 membrane-feeding 
experiments carried out using gametocyte-infected blood from 
eight different P. vivax patients and the results are presented 
in Table 1. Feedings were carried out using sera obtained after 
either  three or five immunizations  as  detailed in  the  table 
legend.  In 8 out of 10 experiments,  the antisera suppressed 
infectivity ofP. vivax gametocytes to a statistically significant 
extent,  as judged  by the number  of parasites  (oocysts) de- 
veloping in  the mosquito,  the infectivity being reduced to 
between 6  and 33%  of the control. Antiserum  obtained at 
three different time points after the fifth injection were tested 
against  the  same  parasite  isolate  (experiments  8-10)  and 
significant infectivity suppressive effects were shown even 6 
wk after immunization. Despite the variability of these results, 
they represent a significant reduction in infectivity. In 5 out 
of the 10 experiments, the immune sera reduced the number 
of mosquitoes infected to g50%  of that in controls and in 
every case there is a reduction in the number of mosquitoes 
infected for the epitope peptide compared to the control (after 
correcting  for the  numbers  of mosquitoes  counted). 
The variability in the infectivity suppressive effects demon- 
strated in these experiments may be explained by the fact that 
each experiment was  performed using gametocyte-infected 
blood from a different infected donor. They are therefore likely 
to differ in the gametocyte count,  the ratio of male and fe- 
male gametocytes, and possibly in recognition of the epitope, 
all of which are known to influence the impact of an infec- 
tivity suppressive antibody. The inability to use a  standard 
parasite isolate for testing is an invariable technical difficulty 
encountered with P.  vivax due to the lack of continuous  in 
vitro  culture. 
It has recently been proposed that control measures aimed 
at decreasing transmission rates of malaria parasites may be 
more effective than previously predicted (19). Moreover, the 
observation  that  a  reduction  of the  levels  of transmission 
through  the  use  of  insecticide  treated  bed  nets  could 
significantly reduce morbidity (20,  21) indicates that trans- 
mission-blocking immunity, even if incomplete, could have 
an impact  on disease as well as reduce the spread of drug- 
or vaccine-resistant parasites. We have thus demonstrated that 
antibodies which  suppress infectivity can be raised in mice 
by immunization with a small peptide. This raises the hope 
that at least in the case of some target antigens of transmission- 
blocking  immunity,  eukaryotic expression of large recom- 
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to Mosquitoes 
Mean oocyst per gut  Percent 
Anti-sera raised  against:  infectivity 
Mann-Whitney 
Expt.  MR  Epitope  Control  U  test 
No.  No.  peptide  peptide  p  value at 95% 
1r  3324  1.6 (8/20)  27.3 (12/20)  5.8%  *p  =  0.0179 
21  3331  12.0 (8/20)  53.1  (19/22)  22.6%  *p  =  0.0003 
3r  3334  16.3  (11/21)  88.9 (11/13)  18.3%  *p  =  0.0008 
4t  3339  20.8 (8/18)  62.5 (9/17)  33.3%  p  =  0.3141 
51  3340  23.5 (10/17)  94.4 (20/21)  24.8%  "p  =  0.0008 
6 o  3393  3.3 (10/17)  31.3 (11/20)  10.5%  p  =  0.0783 
7 II  3396  28.8 (7/20)  94.5 (13/21)  30.5%  *p  =  0.0183 
8S  3398  14.6 (5/22)  56.8 (14/22)  24.7%  *p  =  0.0192 
9fJ  3398  11.4 (5/21)  51.3 (13/20)  22.2%  *p  =  0.0032 
101  3398  18.5  (6/20)  57.9 (14/20)  31.4%  *p  =  0.0155 
The percent infectivity of the A12 epitope peptide (Ep) compared to the control (Tu) is shown for each of the 10 feedings (Expt.  No.) where p 
values correspond to a 95% confidence level for a Mann-Whitney  U test, applied to random samples. The MR No. is the parasite isolate number 
used in each feeding. The number of mosquitoes infected/number  mosquitoes dissected is shown in parentheses for the Ep and Tu peptide serum. 
The mean oocyst per gut is shown after feeding mosquitoes in the presence of antibodies raised against either the epitope or control peptide. 
"p <0.05 is significant. 
I Sera from the third  immunization. 
S Sera from the fifth injection taken 7 d after immunization. 
II Sera from the fifth injection taken 22 d after immunization. 
I Sera from the fifth injection taken 44 d after immunization. 
binant molecules reproducing specific tertiary structures may 
not  be essential. 
Immunization of mice with the A12 epitope peptide led 
to antibodies  that completely blocked parasite development 
in a number of mosquitoes, and significantly lowered oocyst 
burdens  using  experimental  infections  of laboratory  mos- 
quitoes. Similar results, if they were to be obtained in natural 
infections, where oocyst numbers are usually lower than those 
obtained here, could have significant effects on P. vivax inci- 
dence  and  morbidity. 
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